Literature DB >> 22549228

Therapy: Azithromycin and decolonization after HUS.

Michael E Seifert, Phillip I Tarr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22549228     DOI： 10.1038/nrneph.2012.87

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis.

Authors:  Craig S Wong; Jody C Mooney; John R Brandt; Amy O Staples; Srdjan Jelacic; Daniel R Boster; Sandra L Watkins; Phillip I Tarr
Journal:  Clin Infect Dis       Date:  2012-03-19       Impact factor: 9.079

2.  Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain.

Authors:  Martina Bielaszewska; Evgeny A Idelevich; Wenlan Zhang; Andreas Bauwens; Frieder Schaumburg; Alexander Mellmann; Georg Peters; Helge Karch
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

3.  Desperately seeking diarrhoea: outbreak of haemolytic uraemic syndrome caused by emerging sorbitol-fermenting shiga toxin-producing Escherichia coli O157:H-, Germany, 2009.

Authors:  S Nielsen; C Frank; A Fruth; A Spode; R Prager; A Graff; A Plenge-Bönig; S Loos; M Lütgehetmann; M J Kemper; D E Müller-Wiefel; D Werber
Journal:  Zoonoses Public Health       Date:  2011-04-06       Impact factor: 2.702

4.  Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.

Authors:  Julie A Ake; Srdjan Jelacic; Marcia A Ciol; Sandra L Watkins; Karen F Murray; Dennis L Christie; Eileen J Klein; Phillip I Tarr
Journal:  Pediatrics       Date:  2005-06       Impact factor: 7.124

5.  Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4.

Authors:  Martin Nitschke; Friedhelm Sayk; Christoph Härtel; Rahel Tabea Roseland; Susanne Hauswaldt; Jürgen Steinhoff; Klaus Fellermann; Inge Derad; Peter Wellhöner; Jürgen Büning; Bettina Tiemer; Alexander Katalinic; Jan Rupp; Hendrik Lehnert; Werner Solbach; Johannes K-M Knobloch
Journal:  JAMA       Date:  2012-03-14       Impact factor: 56.272

6.  Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome.

Authors:  Christina A Hickey; T James Beattie; Jennifer Cowieson; Yosuke Miyashita; C Frederic Strife; Juliana C Frem; Johann M Peterson; Lavjay Butani; Deborah P Jones; Peter L Havens; Hiren P Patel; Craig S Wong; Sharon P Andreoli; Robert J Rothbaum; Anne M Beck; Phillip I Tarr
Journal:  Arch Pediatr Adolesc Med       Date:  2011-07-22

7.  Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota.

Authors:  Kirk E Smith; Peter R Wilker; Paul L Reiter; Erin B Hedican; Jeff B Bender; Craig W Hedberg
Journal:  Pediatr Infect Dis J       Date:  2012-01       Impact factor: 2.129

8.  Preventing household transmission of Shiga toxin-producing Escherichia coli O157 infection: promptly separating siblings might be the key.

Authors:  Dirk Werber; Brendan W Mason; Meirion R Evans; Roland L Salmon
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

9.  Transmission of Escherichia coli O157:H7 infection in Minnesota child day-care facilities.

Authors:  E A Belongia; M T Osterholm; J T Soler; D A Ammend; J E Braun; K L MacDonald
Journal:  JAMA       Date:  1993-02-17       Impact factor: 56.272

10.  Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis.

Authors:  Nasia Safdar; Adnan Said; Ronald E Gangnon; Dennis G Maki
Journal:  JAMA       Date:  2002-08-28       Impact factor: 56.272
  10 in total
  5 in total

1.  Azithromycin decolonization of STEC--a new risk emerges.

Authors:  Michael E Seifert; Phillip I Tarr
Journal:  Nat Rev Nephrol       Date:  2012-06-05       Impact factor: 28.314

Review 2.  Shiga toxin-producing Escherichia coli O104:H4: an emerging pathogen with enhanced virulence.

Authors:  Dakshina M Jandhyala; Vijay Vanguri; Erik J Boll; Yushuan Lai; Beth A McCormick; John M Leong
Journal:  Infect Dis Clin North Am       Date:  2013-07-24       Impact factor: 5.982

3.  Hemolytic uremic syndrome in a 65-Year-old male linked to a very unusual type of stx2e- and eae-harboring O51:H49 shiga toxin-producing Escherichia coli.

Authors:  Dominique Fasel; Alexander Mellmann; Nicole Cernela; Herbert Hächler; Angelika Fruth; Nina Khanna; Adrian Egli; Christiane Beckmann; Hans H Hirsch; Daniel Goldenberger; Roger Stephan
Journal:  J Clin Microbiol       Date:  2014-02-05       Impact factor: 5.948

Review 4.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 5.  Renal and neurological involvement in typical Shiga toxin-associated HUS.

Authors:  Howard Trachtman; Catherine Austin; Maria Lewinski; Rolf A K Stahl
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.